登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由中山大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07487662,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
1) Age: 18-75 years old; 2) Patients with hepatocellular carcinoma (HCC) classified as CNLC stage Ib-IIIa (excluding patients with Vp3 and Vp4), and deemed resectable by multidisciplinary team (MDT) discussion;
入选标准第 1 条
1) Prior history of HCC treatment; 2) Tumor rupture and bleeding, or suspected peritoneal metastasis;
排除标准第 1 条
Untreated active hepatitis B subjects (HBsAg positive and HBV-DNA exceeding 5000 copies/mL (1000 IU/mL) or higher than the lower limit of detection, whichever is higher); for subjects with hepatitis B, anti-hepatitis B virus treatment is required during the study treatment; active hepatitis C subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection);
排除标准第 9 条
ECOG PS score of 0-1;
入选标准第 4 条
Hemoglobin concentration ≥ 90 g/L;
入选标准第 8 条
Neutrophil count ≥ 1.5 × 10⁹/L;
入选标准第 9 条
Platelet count ≥ 75 × 10⁹/L;
入选标准第 10 条
Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal);
入选标准第 11 条
AST and ALT < 5 × ULN; ALP < 4 × ULN;
入选标准第 12 条
Creatinine ≤ 1.5 × ULN;
入选标准第 13 条
INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN;
入选标准第 14 条
At least one measurable target lesion according to the RECIST 1.1 criteria;
入选标准第 3 条
Prior positive HIV test or acquired immunodeficiency syndrome (AIDS);
排除标准第 12 条
Women of childbearing age must be excluded from pregnancy;
入选标准第 16 条
Pregnant or lactating women, or subjects planning to have children during the trial period;
排除标准第 22 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07487662,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1) Age: 18-75 years old; 2) Patients with hepatocellular carcinoma (HCC) classified as CNLC stage Ib-IIIa (excluding patients with Vp3 and Vp4), and deemed resectable by multidisciplinary team (MDT) discussion; No prior tumor-related treatment received; At least one measurable target lesion according to the RECIST 1.1 criteria; ECOG PS score of 0-1; Liver function classification: Child-Pugh Class A; Estimated survival time ≥ 12 weeks; Hematological, liver, and renal functions meet the following criteria: Hemoglobin concentration ≥ 90 g/L; Neutrophil count ≥ 1.5 × 10⁹/L; Platelet count ≥ 75 × 10⁹/L; Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal); AST and ALT < 5 × ULN; ALP < 4 × ULN; Creatinine ≤ 1.5 × ULN; INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN; Serum albumin concentration ≥ 30 g/L; Women of childbearing age must be excluded from pregnancy; For patients with other concurrent malignant tumors, MDT discussion must confirm that the history and treatment history of other tumors will not interfere with the efficacy and safety evaluation of this study protocol; Ability to understand and sign the informed consent form.排除标准:Exclusion Criteria:
1) Prior history of HCC treatment; 2) Tumor rupture and bleeding, or suspected peritoneal metastasis; History of other complex surgeries within 6 weeks; Prior history of organ transplantation; Currently receiving treatment in other clinical trials; Prior history of autoimmune diseases, inflammatory disorders (such as inflammatory bowel disease, etc.), diverticulitis, systemic lupus erythematosus, sarcoidosis syndrome, Wegener's syndrome (granulomatosis with polyangiitis, rheumatoid arthritis, etc.), except for the following cases: vitiligo or alopecia areata, hypothyroidism with stable condition after drug replacement therapy, chronic skin diseases that do not require systemic treatment, and celiac disease controllable by diet alone; Prior history of allergy to anti-PD1 drugs, TKI or anti-CTLA4 drugs, or allergy to chemical molecules similar to the above drugs, or prior severe allergic reaction to other monoclonal antibodies; Uncontrollable intermittent recurrent diseases, including but not limited to: persistent infections (including tuberculosis), hypertension uncontrollable by drugs (> 140/90 mmHg), interstitial lung disease, severe chronic gastrointestinal diseases complicated with diarrhea, mental illness or social disorders that cannot comply with clinical research requirements, factors with high risk of side effects, and inability to sign the informed consent form; Patients with prior hepatic encephalopathy, refractory ascites, or esophagogastric varices with high bleeding risk; patients with upper gastrointestinal bleeding within 1 year before the first administration; Untreated active hepatitis B subjects (HBsAg positive and HBV-DNA exceeding 5000 copies/mL (1000 IU/mL) or higher than the lower limit of detection, whichever is higher); for subjects with hepatitis B, anti-hepatitis B virus treatment is required during the study treatment; active hepatitis C subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection); Patients with primary brain tumors (except meningiomas or other benign brain tumors), or any brain metastases, leptomeningeal carcinomatosis, epilepsy uncontrollable by conventional drugs, or new-onset stroke within 1 year; Primary immunodeficiency disease; Prior positive HIV test or acquired immunodeficiency syndrome (AIDS); Use of immunosuppressive drugs within 14 days before the start of study treatment. The following situations are exempt: Intranasal, inhaled, topically used steroids or local steroid injections; Systemic application of corticosteroids not exceeding the physiological dose (e.g., 10 mg/day prednisone or its equivalent); Steroid application for the treatment of allergic reactions; Vaccination with live-attenuated vaccines within 30 days before the start of study treatment. Note: Live-attenuated vaccines should also be avoided during the study treatment and within 30 days after the end of treatment; Receipt of systemic immunostimulant treatment within the prior 4 weeks; Prior history of severe systemic diseases, including: myocardial infarction or unstable angina pectoris, hypertensive crisis or hypertensive encephalopathy, congestive heart failure of NYHA Class II or above, unstable symptomatic arrhythmia requiring drug intervention, severe vascular disease or symptomatic peripheral vascular disease, occurring within 12 months before the start of study treatment; History of coagulative, hemorrhagic or thrombotic diseases within 12 months before the start of study treatment; Severe, irreversible trauma, ulcers or fractures; Pregnant or lactating women, or subjects planning to have children during the trial period; Dependent on parenteral nutrition to maintain life; Other acute or chronic diseases, mental and psychological diseases, etc., which are not suitable for participating in this study, as judged by the researcher.
引自 ClinicalTrials.gov, NCT07487662, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07487662,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。